Association of total and bioactive serum sclerostin levels with bone metabolism in type 2 diabetes mellitus
Background: Sclerostin has been associated with decreased bone turnover in patients with type 2 diabetes mellitus (T2DM). The relationship with bone turnover markers (BTMs) and bone mineral density (BMD) remains unclear. We investigate the relationship between total and bioactive sclerostin measured...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | Journal of Clinical & Translational Endocrinology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2214623725000110 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849699394990899200 |
|---|---|
| author | Cyril Traechslin Lilian Sewing Sandra Baumann Leticia Grize Janina Vavanikunnel Marius Kraenzlin Christoph Henzen Christian Meier |
| author_facet | Cyril Traechslin Lilian Sewing Sandra Baumann Leticia Grize Janina Vavanikunnel Marius Kraenzlin Christoph Henzen Christian Meier |
| author_sort | Cyril Traechslin |
| collection | DOAJ |
| description | Background: Sclerostin has been associated with decreased bone turnover in patients with type 2 diabetes mellitus (T2DM). The relationship with bone turnover markers (BTMs) and bone mineral density (BMD) remains unclear. We investigate the relationship between total and bioactive sclerostin measured by three different assays with BTMs and BMD in patients with T2DM compared to healthy controls. Methods: Baseline data from the cross-sectional multicenter DiabOS-study in Switzerland were analysed. Total and bioactive serum sclerostin levels were measured using three different ELISA-based sclerostin assays (Sclerostin Biomedica, Sclerostin bioactive Biomedica and Sclerostin hsTECO). Sclerostin levels in patients with T2DM and controls were correlated with BTMs and BMD. Results: Data were analysed from 78 men and postmenopausal women with T2DM and 37 controls (aged 50–75 years). Serum sclerostin levels, adjusted for estimated glomerular filtration rate (eGFR), were higher in patients with T2DM compared to controls with all three assays. In a gender subgroup analysis, bioactive sclerostin levels remained significantly elevated in men with T2DM (T2DM, 106.8 ± 39.9 pmol/L; controls, 88.3 ± 21.3 pmol/L, p = 0.03).Univariate analysis showed consistent significant correlations with all sclerostin assays for age, eGFR, glycated hemoglobin A1c and diabetes duration. However, in multivariate analysis, eGFR remained the only significant determinant of serum sclerostin levels. Sclerostin levels in patients with T2DM showed significant positive correlations with BMD but no significant correlations with BTMs. Conclusions: We demonstrate a significant positive association of bioactive serum sclerostin with BMD at all measured sites in patients with T2DM, which may support its utility in the assessment of bone fragility in this population. |
| format | Article |
| id | doaj-art-a885ee48ec4d44d186439f1fca3dda6c |
| institution | DOAJ |
| issn | 2214-6237 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Clinical & Translational Endocrinology |
| spelling | doaj-art-a885ee48ec4d44d186439f1fca3dda6c2025-08-20T03:18:37ZengElsevierJournal of Clinical & Translational Endocrinology2214-62372025-06-014010039310.1016/j.jcte.2025.100393Association of total and bioactive serum sclerostin levels with bone metabolism in type 2 diabetes mellitusCyril Traechslin0Lilian Sewing1Sandra Baumann2Leticia Grize3Janina Vavanikunnel4Marius Kraenzlin5Christoph Henzen6Christian Meier7Division of Endocrinology, Diabetes and Metabolism, University Hospital Basel, Petersgraben 4, 4031 Basel, SwitzerlandDivision of Endocrinology, Diabetes and Metabolism, University Hospital Basel, Petersgraben 4, 4031 Basel, SwitzerlandDivision of Endocrinology and Diabetes, Hospital Emmental, Oberburgstrasse 54, 3400 Burgdorf, SwitzerlandSwiss Tropical and Public Health Institute and University of Basel, Kreuzstrasse 2, 4123 Allschwil, SwitzerlandDivision of Endocrinology, Olten Cantonal Hospital, Baslerstrasse 150, 4600 Olten, SwitzerlandEndocrine Clinic and Laboratory, Aeschenvorstadt 57, 4051 Basel, SwitzerlandDepartment of Internal Medicine, Lucerne Cantonal Hospital, Spitalstrasse, 6000 Luzern 16, SwitzerlandDivision of Endocrinology, Diabetes and Metabolism, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland; Endocrine Clinic and Laboratory, Aeschenvorstadt 57, 4051 Basel, Switzerland; Corresponding author.Background: Sclerostin has been associated with decreased bone turnover in patients with type 2 diabetes mellitus (T2DM). The relationship with bone turnover markers (BTMs) and bone mineral density (BMD) remains unclear. We investigate the relationship between total and bioactive sclerostin measured by three different assays with BTMs and BMD in patients with T2DM compared to healthy controls. Methods: Baseline data from the cross-sectional multicenter DiabOS-study in Switzerland were analysed. Total and bioactive serum sclerostin levels were measured using three different ELISA-based sclerostin assays (Sclerostin Biomedica, Sclerostin bioactive Biomedica and Sclerostin hsTECO). Sclerostin levels in patients with T2DM and controls were correlated with BTMs and BMD. Results: Data were analysed from 78 men and postmenopausal women with T2DM and 37 controls (aged 50–75 years). Serum sclerostin levels, adjusted for estimated glomerular filtration rate (eGFR), were higher in patients with T2DM compared to controls with all three assays. In a gender subgroup analysis, bioactive sclerostin levels remained significantly elevated in men with T2DM (T2DM, 106.8 ± 39.9 pmol/L; controls, 88.3 ± 21.3 pmol/L, p = 0.03).Univariate analysis showed consistent significant correlations with all sclerostin assays for age, eGFR, glycated hemoglobin A1c and diabetes duration. However, in multivariate analysis, eGFR remained the only significant determinant of serum sclerostin levels. Sclerostin levels in patients with T2DM showed significant positive correlations with BMD but no significant correlations with BTMs. Conclusions: We demonstrate a significant positive association of bioactive serum sclerostin with BMD at all measured sites in patients with T2DM, which may support its utility in the assessment of bone fragility in this population.http://www.sciencedirect.com/science/article/pii/S2214623725000110SclerostinBioactive sclerostinType 2 diabetes mellitusOsteoporosisBone metabolism |
| spellingShingle | Cyril Traechslin Lilian Sewing Sandra Baumann Leticia Grize Janina Vavanikunnel Marius Kraenzlin Christoph Henzen Christian Meier Association of total and bioactive serum sclerostin levels with bone metabolism in type 2 diabetes mellitus Journal of Clinical & Translational Endocrinology Sclerostin Bioactive sclerostin Type 2 diabetes mellitus Osteoporosis Bone metabolism |
| title | Association of total and bioactive serum sclerostin levels with bone metabolism in type 2 diabetes mellitus |
| title_full | Association of total and bioactive serum sclerostin levels with bone metabolism in type 2 diabetes mellitus |
| title_fullStr | Association of total and bioactive serum sclerostin levels with bone metabolism in type 2 diabetes mellitus |
| title_full_unstemmed | Association of total and bioactive serum sclerostin levels with bone metabolism in type 2 diabetes mellitus |
| title_short | Association of total and bioactive serum sclerostin levels with bone metabolism in type 2 diabetes mellitus |
| title_sort | association of total and bioactive serum sclerostin levels with bone metabolism in type 2 diabetes mellitus |
| topic | Sclerostin Bioactive sclerostin Type 2 diabetes mellitus Osteoporosis Bone metabolism |
| url | http://www.sciencedirect.com/science/article/pii/S2214623725000110 |
| work_keys_str_mv | AT cyriltraechslin associationoftotalandbioactiveserumsclerostinlevelswithbonemetabolismintype2diabetesmellitus AT liliansewing associationoftotalandbioactiveserumsclerostinlevelswithbonemetabolismintype2diabetesmellitus AT sandrabaumann associationoftotalandbioactiveserumsclerostinlevelswithbonemetabolismintype2diabetesmellitus AT leticiagrize associationoftotalandbioactiveserumsclerostinlevelswithbonemetabolismintype2diabetesmellitus AT janinavavanikunnel associationoftotalandbioactiveserumsclerostinlevelswithbonemetabolismintype2diabetesmellitus AT mariuskraenzlin associationoftotalandbioactiveserumsclerostinlevelswithbonemetabolismintype2diabetesmellitus AT christophhenzen associationoftotalandbioactiveserumsclerostinlevelswithbonemetabolismintype2diabetesmellitus AT christianmeier associationoftotalandbioactiveserumsclerostinlevelswithbonemetabolismintype2diabetesmellitus |